Detalhe da pesquisa
1.
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Br J Haematol
; 174(4): 571-81, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27101934
2.
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective.
Ther Innov Regul Sci
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704515
3.
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Int J Hematol
; 117(5): 729-737, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690910
4.
A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos.
J Cell Sci
; 123(Pt 11): 1862-72, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20442250
5.
An overview of the BOIN design and its current extensions for novel early-phase oncology trials.
Contemp Clin Trials Commun
; 28: 100943, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35812822
6.
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Cancer Med
; 11(24): 4889-4899, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35619325
7.
Critical review of oncology clinical trial design under non-proportional hazards.
Crit Rev Oncol Hematol
; 162: 103350, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989767
8.
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy.
Contemp Clin Trials Commun
; 16: 100461, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31799471
9.
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.
Contemp Clin Trials Commun
; 10: 62-76, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29696160
10.
Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Contemp Clin Trials Commun
; 5: 34-48, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29740620
11.
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
J Drug Assess
; 6(1): 10-17, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28959500
12.
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
Blood Adv
; 1(15): 1167-1180, 2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296758
13.
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Clin Cancer Res
; 22(19): 4807-4816, 2016 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27154915
14.
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
J Clin Oncol
; 32(2): 68-75, 2014 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24323026
15.
Design of oncology clinical trials: a review.
Crit Rev Oncol Hematol
; 88(1): 144-53, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23623356
16.
Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigm.
Crit Rev Oncol Hematol
; 83(2): 153-69, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22118941
17.
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Eur J Cancer
; 48(2): 253-62, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22033322
18.
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
J Clin Oncol
; 29(21): 2933-40, 2011 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690471
19.
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
J Clin Oncol
; 28(18): 3076-83, 2010 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20479403
20.
The forces behind cell movement.
Int J Biol Sci
; 3(5): 303-17, 2007 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17589565